Pfizer (PFE) Tops Q4 EPS by 20c, Revenue Misses, Guidance Falls Short of Views
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.80 -1.14%
Revenue Growth %: -4.6%
Financial Fact:
Less: Net income attributable to noncontrolling interests: 0
Today's EPS Names:
TAYD, PKE, More
Revenue Growth %: -4.6%
Financial Fact:
Less: Net income attributable to noncontrolling interests: 0
Today's EPS Names:
TAYD, PKE, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q4 EPS of $1.08, $0.20 better than the analyst estimate of $0.88. Revenue for the quarter came in at $23.8 billion versus the consensus estimate of $24.17 billion.
GUIDANCE:
Pfizer sees FY2022 EPS of $6.35-$6.55, versus the consensus of $6.65. Pfizer sees FY2022 revenue of $98-102 billion, versus the consensus of $106.5 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment
- Integra LifeSciences cuts 2026 outlook after Cincinnati flood
- FactSet (FDS) Tops Q4 EPS by 17c, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
